{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T23:24:02Z","timestamp":1764458642517},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,5,6]],"date-time":"2006-05-06T00:00:00Z","timestamp":1146873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s00280-006-0205-x","type":"journal-article","created":{"date-parts":[[2006,5,5]],"date-time":"2006-05-05T13:07:58Z","timestamp":1146834478000},"page":"585-593","source":"Crossref","is-referenced-by-count":9,"title":["Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation"],"prefix":"10.1007","volume":"58","author":[{"given":"Giacomo","family":"Allegrini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Cerri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samanta","family":"Cupini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Amatori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Del Tacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,5,6]]},"reference":[{"key":"205_CR1","first-page":"5944","volume":"47","author":"T Kunimoto","year":"1987","unstructured":"Kunimoto T, Nitta K, Kanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10 (4-(1-piperidino)-1 piperidino)-1-carboniloxi-campthotecin, a novel water soluble derivative of campthotecin, against murine tumor. Cancer Res 47:5944\u20135947","journal-title":"Cancer Res"},{"key":"205_CR2","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1996.14.10.2688","volume":"14","author":"P Canal","year":"1996","unstructured":"Canal P, Gay C, Dazeuse A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14:2688\u20132695","journal-title":"J Clin Oncol"},{"key":"205_CR3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","volume":"21","author":"CS; MR Fuchs Moore","year":"2003","unstructured":"Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807\u2013814","journal-title":"J Clin Oncol"},{"key":"205_CR4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjc.6600725","volume":"88","author":"S Negoro","year":"2003","unstructured":"Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M; CPT-11 Lung Cancer Study Group West (2003) Randomized phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88:335\u2013341","journal-title":"Br J Cancer"},{"key":"205_CR5","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","volume":"17","author":"HS Friedman","year":"1999","unstructured":"Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL (1999) Irinotecan therapy in adults with recurrent or progressiv malignant glioma. J Clin Oncol 17:1516\u20131525","journal-title":"J Clin Oncol"},{"key":"205_CR6","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2004.10.047","volume":"22","author":"EA Perez","year":"2004","unstructured":"Perez EA, Hillman DW, Mailliard JA, Ingle JN, Ryan JM, Fitch TR, Rowland KM, Kardinal CG, Krook JE, Kugler JW, Dakhil SR (2004) Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 22:2849\u20132855","journal-title":"J Clin Oncol"},{"key":"205_CR7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.bjc.6601226","volume":"89","author":"CH Kohene","year":"2003","unstructured":"Kohene CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ (2003) Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicenter trial. Br J Cancer 89:997\u20131001","journal-title":"Br J Cancer"},{"key":"205_CR8","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1200\/JCO.1997.15.8.2910","volume":"15","author":"HC Pitot","year":"1997","unstructured":"Pitot HC, Wender DB, O\u2019Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE (1997) Phase II trial of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 15:2910\u20132919","journal-title":"J Clin Oncol"},{"key":"205_CR9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1997.15.1.251","volume":"15","author":"P Rougier","year":"1997","unstructured":"Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-na\u00efve patients and patients pretreated with fluorouracil based chemotherapy. J Clin Oncol 15:251\u2013260","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"205_CR10","first-page":"6","volume":"26","author":"D Cunningham","year":"1999","unstructured":"Cunningham D, Glimelius B (1999) A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. Sem Oncol 26(suppl 5):6\u201310","journal-title":"Sem Oncol"},{"key":"205_CR11","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(98)03085-2","volume":"352","author":"P Rougier","year":"1998","unstructured":"Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C (1998) Randomized trial of irinotecan versus fluorouracil by continous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407\u20131412","journal-title":"Lancet"},{"key":"205_CR12","unstructured":"Graeven U, Ridwelski K, Manns M (2000) Irinotecan with bolus 5-fluorouracil and folinic acid in patients with previously untreated metastatic colorectal cancer: an active and safe regiment. Proc Am Soc Clin Oncol 19 abstract no. 952"},{"key":"205_CR13","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","volume":"355","author":"JY Douillard","year":"2000","unstructured":"Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 355:1041\u20131047","journal-title":"Lancet"},{"key":"205_CR14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905\u2013914","journal-title":"N Engl J Med"},{"key":"205_CR15","doi-asserted-by":"crossref","unstructured":"Saltz LB, Niedzwiecki D, Hollis D (2004) Irinotecan plus fluorouracil\/leucovorin (IFL) versus fluorouracil\/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803). Proc Am Soc Clin Oncol 22: abstract no. 3500","DOI":"10.1200\/jco.2004.22.90140.3500"},{"key":"205_CR16","unstructured":"Sasaki K, Takasaka H, Kiriyama K (2004) Adjuvant postoperative chemotherapy for Dukes C colorectal cancer; weekly low-dose Irinotecan (CPT-11) plus 5 FU versus oral 5FU only. Proc Am Soc Clin Oncol 22: abstract no. 3735"},{"key":"205_CR17","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1996.14.10.2688","volume":"10","author":"P Canal","year":"1996","unstructured":"Canal P, Gay C, Dezeuse A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F, Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 10:2688\u20132695","journal-title":"J Clin Oncol"},{"key":"205_CR18","first-page":"4347","volume":"54","author":"M Forni De","year":"1994","unstructured":"De Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A (1994) Phase I and pharmacokinetics study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347\u20134354","journal-title":"Cancer Res"},{"key":"205_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1200\/JCO.1995.13.1.210","volume":"13","author":"D Abigerges","year":"1995","unstructured":"Abigerges D, Chabot GG, Armand J, Herait P, Gouyette A, Gandia D (1995) Phase I and pharmacologic studies of the camptothecin analogue irinotecan administered every 3 weeks in cancer ptients. J Clin Oncol 13:210\u2013221","journal-title":"J Clin Oncol"},{"key":"205_CR20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/oxfordjournals.annonc.a059108","volume":"6","author":"G Catimel","year":"1995","unstructured":"Catimel G, Chabot GG, Guastella JP, Dumortier A, Cote C, Engel C, Gouyette A, Mathieu-Boue A, Mahjoubi M, Clavel M (1995) Phase I and pharmacokinetics study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advances solid tumors. Ann Oncol 6:133\u2013140","journal-title":"Ann Oncol"},{"issue":"suppl 3","key":"205_CR21","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/0959-8049(96)00293-6","volume":"32A","author":"H Bleiberg","year":"1996","unstructured":"Bleiberg H, Cvitkovic E (1996) Characterisation and clinical management of CPT-11 induced adverse events: the european perspective. Eur J Cancer 32A(suppl 3):S18\u2013S23","journal-title":"Eur J Cancer"},{"key":"205_CR22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.1996.14.3.709","volume":"14","author":"JA Conti","year":"1996","unstructured":"Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C (1996) Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709\u2013715","journal-title":"J Clin Oncol"},{"key":"205_CR23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/jnci\/86.6.446","volume":"86","author":"D Abigerges","year":"1994","unstructured":"Abigerges D, Armand JP, Chabot GC, Da Costa L, Fadel E, Cote C, Herait P, Gandia D (1994) Irinotecan high-dose escalation using intensive high-dose loperamide to control diarrhea. J Nat Cancer Inst 86:446\u2013449","journal-title":"J Nat Cancer Inst"},{"key":"205_CR24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S0006-2952(99)00388-3","volume":"59","author":"TD Stephens","year":"2000","unstructured":"Stephens TD, Bunde CJ, Fillemore BJ (2000) Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59:1489\u20131499","journal-title":"Biochem Pharmacol"},{"key":"205_CR25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2249.1995.tb05527.x","volume":"99","author":"SM McHugh","year":"1995","unstructured":"McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW ( (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160\u2013167","journal-title":"Clin Exp Immunol"},{"key":"205_CR26","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1006\/exer.1997.0292","volume":"64","author":"BM Kenyon","year":"1997","unstructured":"Kenyon BM, Browne F, D\u2019Amato RJ (1997) Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971\u2013978","journal-title":"Exp Eye Res"},{"key":"205_CR27","first-page":"217","volume":"26","author":"R Or","year":"1998","unstructured":"Or R, Feferman R, Shoshan S (1998) Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs. Exp Hematol 26:217\u2013221","journal-title":"Exp Hematol"},{"key":"205_CR28","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565\u20131571","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"205_CR29","first-page":"316a","volume":"94","author":"SV Rajkumar","year":"1999","unstructured":"Rajkumar SV, Fonseca R, Dispenzieri A, et al (1999) Thalidomide in the treatment of relapsed and refractory myeloma. Blood 94(suppl 1):316a","journal-title":"Blood"},{"key":"205_CR30","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","volume":"18","author":"HA Fine","year":"2000","unstructured":"Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK (2000) A phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18:708\u2013715","journal-title":"J Clin Oncol"},{"key":"205_CR31","first-page":"1888","volume":"7","author":"WD Figg","year":"2001","unstructured":"Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon S, Kohler DR, Kruger EA, Gubish E, Pluda JM, Reed E (2001) A Randomized phase II trial of docetaxel (taxotere) plus thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888\u20131893","journal-title":"Clin Cancer Res"},{"key":"205_CR32","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/JCO.2002.20.1.302","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Berg W, Ginsberg M, Russo P, Vuky J, Yu R, Bacik J, Mazumdar M (2002) Phase II trial of Thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302\u2013306","journal-title":"J Clin Oncol"},{"key":"205_CR33","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0140-6736(00)02586-1","volume":"356","author":"R Govindarajan","year":"2000","unstructured":"Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M (2000) Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet 356:566\u2013567","journal-title":"Lancet"},{"issue":"suppl","key":"205_CR34","first-page":"23","volume":"16","author":"R Govindarajan","year":"2000","unstructured":"Govindarajan R (2000) Irinotecan\/thalidomide in metastatic colorectal cancer. Oncology 16(suppl):23\u201326","journal-title":"Oncology"},{"key":"205_CR35","unstructured":"Govindarajan R, Maddox A, Gray P (2003) Irinotecan and thalidomide prolong disease free and overall survival in 5FU refractory metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:249: abstract no. 997"},{"key":"205_CR36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0378-4347(92)80156-K","volume":"575","author":"I Barileiro","year":"1992","unstructured":"Barileiro I, Gandia D, Armand JP, Mathieu-Boue A, Re M, Gouyette A, Chabot GG (1992) Simultaneus determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetics studies in cancer patients. J Chromatogr Biomed Appl 575:275\u2013280","journal-title":"J Chromatogr Biomed Appl"},{"key":"205_CR37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National Cancer Institute of United states, National Cancer Institute Of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"205_CR38","unstructured":"Friedman LM, Furberg DC, De Mets DL. Fundamentals of clinical trials. Third Edition, Springer"},{"key":"205_CR39","first-page":"2202","volume":"8","author":"KR Crews","year":"2002","unstructured":"Crews KR, Stewart CF, Jones-Wallace D, Thompson SJ, Houghton PJ, Heideman RL, Fouladi M, Bowers DC, Chintagumpala MM, Gajjar A (2002) Altered irinotecan pharmacokinetics in pediatric high-grade glioma patients receiving enzyme-inducing anticonvulsant therapy. Clin Cancer Res 8:2202\u20132209","journal-title":"Clin Cancer Res"},{"key":"205_CR40","first-page":"3723","volume":"54","author":"E Gupta","year":"1994","unstructured":"Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ (1994) Metabolic fate of irinotecan in humans: correlation of glicuronation with diarrhea. Cancer Res 54:3723\u20133725","journal-title":"Cancer Res"},{"key":"205_CR41","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1997.15.4.1502","volume":"15","author":"E Gupta","year":"1997","unstructured":"Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ (1997) Pharmacokinetic and pharmacodinamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502\u20131510","journal-title":"J Clin Oncol"},{"key":"205_CR42","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/JCO.1996.14.7.2012","volume":"14","author":"R Mick","year":"1996","unstructured":"Mick R, Gupta E, Vokes EE, Ratain MJ (1996) Limited sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012\u20132019","journal-title":"J Clin Oncol"},{"key":"205_CR43","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/PL00005049","volume":"356","author":"MC Haaz","year":"1997","unstructured":"Haaz MC, Rivory LP, Riche C, Robert J (1997) The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 356:257\u2013262","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"205_CR44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/dmd.30.6.731","volume":"30","author":"V Charasson","year":"2002","unstructured":"Charasson V, Haaz MC, Robert J (2002) Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab Dispos 30:731\u2013733","journal-title":"Drug Metab Dispos"},{"key":"205_CR45","first-page":"769","volume":"26","author":"MC Haaz","year":"1998","unstructured":"Haaz MC, Riche C, Rivory LP, Robert J (1998) Biosynthesis of an aminopiperidino metabolite of irinotecan [7\u2013ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes. Drug Metab Dispos 26:769\u2013774","journal-title":"Drug Metab Dispos"},{"key":"205_CR46","first-page":"1964","volume":"8","author":"Y Ando","year":"2002","unstructured":"Ando Y, Fuse E, Figg WD (2002) Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 8:1964\u20131973","journal-title":"Clin Cancer Res"},{"key":"205_CR47","first-page":"1680","volume":"9","author":"J Lu","year":"2003","unstructured":"Lu J, Palmer BD, Kestell P, Browett P, Baguley BC, Muller G, Ching LM (2003) Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res 9:1680\u20131688","journal-title":"Clin Cancer Res"},{"key":"205_CR48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/(SICI)1099-0461(2000)14:3<140::AID-JBT3>3.0.CO;2-P","volume":"14","author":"SK Teo","year":"2000","unstructured":"Teo SK, Sabourin PJ, O\u2019Brien K, Kook KA, Thomas SD (2000) Metabolism of thalidomide in human microsomes, cloned human Cytochrome P-450 isoenzymes, and Hansen\u2019s disease patients. J Biochem Mol Toxicol 14:140\u2013147","journal-title":"J Biochem Mol Toxicol"},{"key":"205_CR49","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1124\/jpet.104.067793","volume":"310","author":"J Lu","year":"2004","unstructured":"Lu J, Helsby N, Palmer BD, Tingle M, Baguley BC, Kestell P, Ching LM (2004) Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans. J Pharmacol Exp Ther 310:571\u2013577","journal-title":"J Pharmacol Exp Ther"},{"key":"205_CR50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1124\/mol.64.1.154","volume":"64","author":"NJ Patel","year":"2003","unstructured":"Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ, Stieger B, Brouwer KL (2003) Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol Pharmacol 64:154\u2013159","journal-title":"Mol Pharmacol"},{"key":"205_CR51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/jpet.103.054197","volume":"307","author":"J Weiss","year":"2003","unstructured":"Weiss J, Kerpen CJ, Lindenmaier H, Dormann SM, Haefeli WE (2003) Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 307:262\u2013267","journal-title":"J Pharmacol Exp Ther"},{"key":"205_CR52","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1124\/dmd.30.9.962","volume":"30","author":"H Xiong","year":"2002","unstructured":"Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, Brouwer KL (2002) Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metab Dispos 30:962\u2013969","journal-title":"Drug Metab Dispos"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0205-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-006-0205-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0205-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T17:51:43Z","timestamp":1627321903000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-006-0205-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,6]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["205"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0205-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,6]]}}}